亚虹医药：关于APL-1401Ib期临床试验获得积极初步结果的公告

Group 1 - The core point of the article is that Yahuang Pharmaceutical announced positive preliminary results from its Phase Ib clinical trial of APL-1401 for the treatment of moderate to severe active ulcerative colitis [2] Group 2 - The clinical trial results indicate that the drug APL-1401 shows promise in treating the specified condition, which could lead to further development and potential market opportunities for the company [2] - The announcement was made on the evening of July 31, highlighting the company's ongoing research efforts in the pharmaceutical industry [2]